2,7-dimethyl-furo[2,3-c]pyridine | 69022-77-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃吡啶类
• 英文名称: 2,7-dimethyl-furo[2,3-c]pyridine
• 英文别名: 2,7-Dimethylfuro[2,3-c]pyridine
• CAS: 69022-77-1
• 化学式: C₉H₉NO
• 分子量: 147.177
• InChiKey: GTIVXIFRBCGCJN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-methyl-3-prop-2-ynyloxy-pyridine 以 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 生成 2,7-dimethyl-furo[2,3-c]pyridine
  参考文献：
  名称：

  Claisen -Umlagerung von 2-Propinyl-（3-pyridyl）-and Allyl-（3-pyridyl）äthern †

  摘要：

  2-丙炔基（3-吡啶基）和烯丙基（3-吡啶基）醚的克莱森重排1

  DOI：

  10.1002/hlca.19780610726

文献信息

• AMIDE COMPOUND
  申请人：Setoh Masaki

  公开号：US20100041891A1

  公开（公告）日：2010-02-18

  A compound having GPR52 agonist activity or a salt thereof is provided. The compound can be provided as a preventive/therapeutic agent for schizophrenia or the like. The compound is represented by the following formula: wherein A represents —CONR a — or —NR a CO—, R a represents a hydrogen atom or the like, B represents a hydrogen atom or the like, a ring Cy1 represents a six-membered aromatic ring which may have one or more substituents in addition to a group represented by -A-B, a ring Cy2 represents a six-membered ring which may be substituted with a halogen atom or the like, a ring Cy3 represents a five- or six-membered ring which may have one or more substituents; X represents C 1-2 alkylene or the like, m represents an integer of 0 to 2, and a ring Cy4 represents a six-membered aromatic ring which may have one or more substituents.

  提供具有GPR52激动剂活性或其盐的化合物。该化合物可作为预防/治疗精神分裂症等疾病的药物。该化合物由以下公式表示：其中A代表—CONRa—或—NRaCO—，Ra代表氢原子或类似物质，B代表氢原子或类似物质，环Cy1代表一个六元芳香环，除了由-A-B表示的基团外，可能有一个或多个取代基，环Cy2代表一个六元环，可能被卤素原子或类似物质取代，环Cy3代表一个有一个或多个取代基的五元或六元环；X代表C1-2烷基或类似物质，m代表0到2之间的整数，环Cy4代表一个六元芳香环，可能有一个或多个取代基。
• 7-AMINOFUROPYRIDINE DERIVATIVES
  申请人：Hornberger Keith R.

  公开号：US20120046267A1

  公开（公告）日：2012-02-23

  Compounds of Formula 1, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by TAK1 or for which an appropriate TAK1 inhibitor is effective. This Abstract is not limiting of the invention.

  公式1的化合物，如下所示并在此定义：其药学上可接受的盐，合成方法，中间体，配方以及使用它们进行疾病治疗的方法，包括治疗癌症，例如由TAK1至少部分驱动的肿瘤或适当的TAK1抑制剂有效的肿瘤。本摘要不限于该发明。
• US8378104B2
  申请人：——

  公开号：US8378104B2

  公开（公告）日：2013-02-19
• [EN] AMIDE COMPOUND<br/>[FR] COMPOSÉ AMIDE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2010018874A1

  公开（公告）日：2010-02-18

  A compound having GPR52 agonist activity or a salt thereof is provided. The compound can be provided as a preventive / therapeutic agent for schizophrenia or the like. The compound is represented by the following formula (Ia): wherein A represents -CONR2- or -NR2CO-, R2 represents a hydrogen atom or the like, B represents a hydrogen atom or the like, a ring CyI represents a six-membered aromatic ring which may have one or more substituents in addition to a group represented by -A-B, a ring Cy2 represents a six-membered ring which may be substituted with a halogen atom or the like, a ring Cy3 represents a five- or six-membered ring which may have one or more substituents; X represents C1-2 alkylene or the like, m represents an integer of 0 to 2, and a ring Cy4 represents a six-membered aromatic ring which may have one or more substituents.
• <i>Claisen</i>-Umlagerung von 2-Propinyl-(3-pyridyl)-und Allyl-(3-pyridyl)äthern
  作者：Jens Bruhn、Janos Zsindely、Hans Schmid、György Fráter

  DOI：10.1002/hlca.19780610726

  日期：1978.11.1

  Claisen Rearrangement of 2-Propinyl (3-Pyridyl) and Allyl (3-Pyridyl) Ethers1

  2-丙炔基（3-吡啶基）和烯丙基（3-吡啶基）醚的克莱森重排1